Guangxi Medical University Cancer Hospital Wuxiang Branch

Nanning, Guangxi 530201

6 studies enrolling now · 6 studies all time

What they study most

Advanced Solid Tumor, Advanced Solid Tumors, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Chronic Lymphocytic Leukemia, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, HR+/HER2- Breast Cancer, Local Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Small Lymphocytic Lymphoma

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting now
• A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Recruiting now